What Does Your Tysabri Medication History Reveal About PML Risk?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specific Product Liability

If you or a loved one took Tysabri and later developed Progressive Multifocal Leukoencephalopathy (PML), you may be wondering how the timeline of medication use connects to the onset of symptoms. Medical records that document exposure duration, dosing intervals, and prior immunosuppressant use are critical for understanding individual risk. Building on decades of clinical research and regulatory monitoring, this page explains how chronology and documentation factor into PML assessment for Michigan patients.

Medical Evidence Linking Tysabri to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Michigan who have developed PML after Tysabri exposure, understanding the medical evidence linking the drug to PML, the adequacy of risk warnings, and the legal timeline for potential settlement claims is critical. The prescribing information for Tysabri contains a boxed warning stating that the drug increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus, which typically only causes disease in immunocompromised individuals. Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment, weighing expected benefit against PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML includes progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and speech difficulties. Diagnosis typically involves brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect reduces immune surveillance, allowing latent JC virus to reactivate and cause lytic infection of oligodendrocytes.

Adequacy of Warnings and Monitoring Requirements

The FDA-approved labeling mandates that healthcare professionals monitor patients on Tysabri for any new sign or symptom suggestive of PML and withhold dosing immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Under this program, prescribers must evaluate patients three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). They must also determine every six months whether patients should continue treatment and submit status reports to the manufacturer (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Cases of PML, hospitalizations due to opportunistic infections, and deaths must be reported to Biogen as soon as possible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether prescribers adequately communicated the PML risk to patients, particularly regarding the significance of anti-JCV antibody status and the cumulative risk over time. For patients who developed PML, the adequacy of warnings is a central issue in settlement considerations.

Settlement Considerations and Statute of Limitations in Michigan

For Michigan patients affected by Tysabri-associated PML, settlement-related considerations involve the timeline between exposure and documented harm. PML typically develops after months to years of Tysabri therapy, with risk increasing beyond two years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The latency period between drug exposure and PML diagnosis can complicate legal claims, as the injury may not become apparent until well after treatment has ended. In Michigan, the statute of limitations for personal injury claims generally requires filing within three years of the date the injury was discovered or should have been discovered. For PML, the 'discovery' date is typically when a patient receives a definitive diagnosis, not when symptoms first appear. However, Michigan law also imposes a six-year statute of repose for product liability claims, meaning no action may be brought more than six years after the time of the injury, regardless of when it was discovered. Given that PML can develop years after Tysabri initiation, patients must carefully document the date of diagnosis and the date of last Tysabri infusion to determine whether their claim falls within these time limits. Settlement negotiations for Tysabri PML claims often consider the severity of disability, medical expenses, lost earnings, and pain and suffering. Because PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), affected patients may face substantial lifetime care costs. The manufacturer's restricted distribution program and mandatory reporting requirements create a documented record of treatment and adverse events, which can support claims. However, patients must also demonstrate that the warnings provided were inadequate or that the prescriber failed to follow monitoring protocols.

Conclusion and Next Steps

The medical evidence clearly establishes that Tysabri increases PML risk, with identifiable risk factors including anti-JCV antibodies, treatment duration, and prior immunosuppressant use. The FDA-mandated boxed warning and TOUCH program require rigorous monitoring and immediate drug cessation at first PML suspicion. For Michigan patients, the statute of limitations and repose periods impose strict deadlines for filing claims, making prompt legal consultation essential. Settlement considerations depend on the timing of diagnosis, adequacy of warnings, and documented harm. Patients should preserve all medical records, including infusion dates, antibody test results, and PML diagnostic reports, to support any potential claim.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Michigan?

In Michigan, the statute of limitations for personal injury claims generally requires filing within three years of the date the injury was discovered or should have been discovered. For PML, the discovery date is typically when a patient receives a definitive diagnosis. Additionally, Michigan has a six-year statute of repose for product liability claims, meaning no action may be brought more than six years after the time of the injury, regardless of when it was discovered. Patients should consult an attorney promptly to ensure their claim is timely.

What medical evidence links Tysabri to PML?

The prescribing information for Tysabri contains a boxed warning stating that the drug increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What is the TOUCH Prescribing Program?

The TOUCH Prescribing Program is a restricted distribution program for Tysabri due to the risk of PML. Under this program, prescribers must evaluate patients at specified intervals, determine whether to continue treatment every six months, and submit status reports to the manufacturer (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Cases of PML must be reported to Biogen as soon as possible.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.